HPV L1 detection discriminates cervical precancer from transient HPV infection: A prospective international multicenter study

Modern Pathology

Volumn 26, Issue 7, 2013, Pages 967-974

  Mehlhorn, Grit ^a   Obermann, Ellen ^b   Negri, Giovanni ^c   Bubendorf, Lukas ^b   Mian, Christine ^c   Koch, Martin ^a   Sander, Heinz ^d   Simm, Birgit ^d   Lütge, Markus ^e   Bánrévi, Zsuzsanna ^e   Weiss, Anke ^f   Cathomas, Gieri ^g   Hilfrich, Ralf ^h   Wilhelm Beckmann, Matthias ^a   Griesser, Henrik ⁱ  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c CENTRAL HOSPITAL OF BOLZANO   (Italy)

^d Cytology Laboratory Einbeck   (Germany)

^e Cytology Laboratory   (Germany)

^f Center of Pathology and Cytodiagnostic   (Germany)

^g Institute of Pathology   (Switzerland)

^h Cytoimmun Diagnostics GmbH   (Germany)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

cervical cancer; HPV L1; prognostic biomarker

Indexed keywords

CAPSID PROTEIN L1; CAPSID PROTEIN; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; COLPOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRECANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS STRAIN; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; REMISSION; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAPSID PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; REMISSION, SPONTANEOUS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84879957570     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.233     Document Type: Article

References (33)

1. Johannesson G, Geirsson G, Day N. The effect of mass screening in Iceland, 1965-74, on the incidence and mortality of cervical carcinoma. Int J Cancer 1978;21: 418-425.
2. Sadler L, Saftlas A, Wang W, et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004;291:2100-2106. (Pubitemid 38580153)
3. Bevis KS, Biggio Jr. Cervical conization and the risk of preterm delivery. Am J Obstet Gynecol 2011;205: 19-27.
4. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 2006;367: 489-498. (Pubitemid 43208905)
5. Nucci MR, Castrillon DH, Bai H, et al. Biomarkers in diagnostic obstetrics and gynaecological pathology: A review. Adv Anat Pathol 2003;10:55-68.
6. The ALTS Group. Human papillomavirus testing for triage of women with cytological evidence of low grade squamous intraepithelial lesions: Baseline data from a randomized trial. J Natl Cancer Inst 2006;92:397-402.
7. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade. Obstet Gynecol 2009;113:18-25.
8. Castle PE, Stoler MH, Solomon D, et al. The Relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality controlreviewed diagnosis. Am J Clin Pathol 2007;127:805-815.
9. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer 2010. available from: Http://globocan.iarc.fr.
10. Riotton G, Christopherson WM, Lunt R. Cytology of the Female Genital Tract. International Histological Classification of Tumours No. 8. World Health Organisation: Geneva, 1973.
11. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119. (Pubitemid 34437346)
12. Wagner D. Munich nomenclature II for gynaecologic cytodiagnosis. Acta Cytol 1990;34:900-901.
13. Cantor SB, Atkinson EN, Cardenas-Turanzas M, et al. Natural History of Cervical Intraepithelial Neoplasia. Acta Cytol 2005;49:405-415. (Pubitemid 41008833)
14. Ostor A. Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 1993; 12:186-192. (Pubitemid 23095196)
15. Soergel P, Makowski E, Makowski L, et al. What are the costs of conisation when considering pregnancy -associated complications? Geb Fra 2011;71:199-204.
16. Rauber D, Mehlhorn G, Fasching PA, et al. Prognostic significance of the detection of the human papillomavirus L1 protein in smears of mild to moderate cervical intraepithelial lesions. Eur J Obstet Gynecol Reprod Biol 2008;140:258-262.
17. Hilfrich R, Hariri J. Prognostic relevance of HPV L1 capsid protein detection within mild to moderate dysplastic lesions of the cervix uteri in combination with a second biomarker p16. Anal Quant Cytol Histol 2008;30:78-82. (Pubitemid 351501867)
18. Negri G, Bellisano G, Zannoni GF, et al. p16 and HPV immunohistochemistry is helpful for estimating the behaviour of low grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008;32:1715-1720.
19. Griesser H, Sander H, Walczak C, et al. HPV vaccine protein L1 predicts disease outcome of high-risk HPV+ early dysplastic lesions. Am J Clin Pathol 2009;132:840-845.
20. Choi YS, Kang WD, Kim SM, et al. Human papillomavirus L1 capsid protein and human papillomavirus type 16 as prognostic markers in cervical intraepithelial neoplasia 1. Int J Gynecol Cancer 2010; 20:288-293.
21. Lee SJ, Lee AW, Kim TJ, et al. Correlation between immunocytochemistry of human papilloma virus L1 capsid protein and behavior of low-grade cervical cytology in Korean women. J Obstet Gynaecol Res 2011;37:1222-1228.
22. Lee H, Lee KJ, Jung CK, et al. Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol 2008;36:864-867.
23. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: Comparison between MY09/MY11 and GP5+/GP6+primer systems. J Clin Microbiol 1997;35:1304-1310. (Pubitemid 27216785)
24. Papanicolaou GN, Traut HF. Diagnosis of uterine cancer by the vaginal smear. Commonwealth Fund: New York, 1943.
25. ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-1400.
26. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: Results from a histological review of population based cervical samples. Int J Gynecol Pathol 2007; 26:441-446. (Pubitemid 47476331)
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33: 159-174. (Pubitemid 8054849)
28. Galgano MT, PhE Castle, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010;34:1077-1087.
29. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers 2007;23:297-313. (Pubitemid 47015790)
30. Stanley M. Immune response to human papillomavirus. Vaccine 2006;24:16-22.
31. Choo KB, Lee HH, Pan CC, et al. Sequence duplication and internal deletion in the integrated human papillomavirus type 16 genome from cervical carcinoma. J Virol 1998;62:1659-1666.
32. Icenogle JP, Clancy KA, Lin SY. Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31. Virology 1995;214:664-669. (Pubitemid 26027797)
33. Yang R, Wheeler CM, Chen X, et al. Papillomavirus capsid mutation to escape dentritic cell dependent innate immunity in cervical cancer. J Virol 2005; 79:6741-6750. (Pubitemid 40677305)